stockrow
Friday 6 November 2026
Export SDGR’s income statement to Excel — free account
Schrodinger, Inc.
SDGR Healthcare Health Information Services
Schrodinger, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $255.9 million, up 23.3% from fiscal 2024.
- Revenue
- +18.7%
- EPS
- −11.1%
- Free cash flow
- +21.6%
Quarter to September 2026, against a year earlier
29.96
1.19
+4.14%
Follow SDGR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.13 | 3.30 | 4.69 | 8.64 | |
P/FCF ratio |
105.42 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(81.60) | (56.66) | (35.64) | (48.86) | |
P/B ratio |
3.61 | 2.68 | 3.69 | 7.70 | |
Price to Tangible BV |
3.66 | 2.72 | 3.75 | 7.83 | |
EV/Sales |
3.56 | 1.70 | 3.07 | 7.25 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
65.53 | (2.99) | (6.27) | (17.33) | |
EV/FCF |
73.12 | (2.93) | (6.10) | (16.71) | |
Quick Ratio |
2.68 | 2.68 | 2.65 | 2.25 | |
Current Ratio |
2.75 | 2.74 | 2.71 | 2.75 | |
Net Debt/EBITDA |
25.59 | 8.59 | 10.45 | 15.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.33 | 0.37 | 0.39 | 0.43 | |
Operating CF/Net income |
(0.49) | 0.25 | (5.70) | 1.26 | |
Capex/Depreciation |
(0.03) | (1.70) | (0.24) | (0.88) | |
Research and Development Expense of Revenue |
47.46% | 74.80% | 69.62% | 52.86% | |
Selling, General and Administrative Expense of Revenue |
37.89% | 58.92% | 56.01% | 46.97% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
11.41% | 15.49% | 14.93% | 12.30% | |
Graham Net Nets |
0.12 | 0.17 | 0.13 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.94%) | (12.41%) | (4.55%) | (2.54%) | |
Free Cash Flow Yield |
0.95% | (17.65%) | (10.73%) | (5.02%) | |
Revenue per Share |
1.19 | 0.79 | 0.79 | 0.86 | |
Operating CF per Share |
(0.22) | (0.20) | (0.46) | (0.64) | |
Capex per Share |
0.00 | (0.03) | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.22) | (0.23) | (0.46) | (0.65) | |
Cash per Share |
5.48 | 5.49 | 5.61 | 4.99 | |
Shareholders Equity per Share |
4.96 | 4.24 | 4.40 | 4.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.96 | 4.24 | 4.40 | 4.03 | |
Free Cash Flow |
(16.13) | (17.34) | (34.43) | (48.87) | |
Working Capital |
330.13 | 294.42 | 296.63 | 290.25 | |
Capital Expenditures |
(0.04) | (2.51) | (0.36) | (1.29) | |
Net Current Asset Value |
157.16 | 143.32 | 159.04 | 146.43 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
179.86 | 47.25 | 38.95 | — | |
Average Payables |
11.06 | 11.90 | 9.56 | 8.58 | |
Average Assets |
774.69 | 688.61 | 664.32 | 632.80 | |
Average Common Equity |
392.75 | 343.53 | 335.91 | 311.59 |
Columns are period end dates · fundamentals updated 4 Nov 2026